How does Syn-Ake compare to Botox?

Different mechanism, different delivery, different intensity. Botox (botulinum toxin) is injected and blocks acetylcholine release from nerve endings — complete paralysis at the injection site. Syn-Ake is applied topically and blocks acetylcholine reception at the muscle — partial relaxation without immobilization. Botox is far more potent but requires medical administration. Syn-Ake is gentler and available over the counter in skincare products.

How does Syn-Ake compare to Argireline (acetyl hexapeptide-8)?

Both reduce wrinkles by limiting muscle contraction, but at different points. Argireline inhibits SNARE complex formation, blocking neurotransmitter release (presynaptic). Syn-Ake blocks the acetylcholine receptor on the muscle itself (postsynaptic). They're often combined in formulations for synergistic effects targeting both sides of the neuromuscular junction.

Does Syn-Ake actually contain snake venom?

No. Syn-Ake is a fully synthetic tripeptide manufactured in a lab. It was designed to mimic the receptor-blocking action of Waglerin-1 from viper venom, but contains no animal-derived ingredients. The 'snake venom' marketing is based on the biomimetic inspiration, not the source material.

Syn-Ake

A synthetic tripeptide that mimics Temple Pit Viper venom, blocking muscular acetylcholine receptors to reduce dynamic wrinkles. Often called 'topical Botox' — reduces muscle contractions by 82% in vitro.

PreliminaryModerate Data Beginner-Friendly

What is Syn-Ake?

Syn-Ake is a patented synthetic tripeptide designed to mimic the paralytic action of Waglerin-1, a peptide found in the venom of the Temple Pit Viper (Tropidolaemus wagleri). It acts as a reversible antagonist of the muscular nicotinic acetylcholine receptor (nmAChR), blocking the signal that tells facial muscles to contract. The result is a topical "Botox-like" muscle-relaxing effect that reduces dynamic wrinkles — the lines caused by repetitive facial expressions like frowning and squinting. At 0.5 mM concentration, Syn-Ake reduces muscle contractions by 82% in isolated tissue preparations. Unlike Botox, which completely paralyzes muscles via injection, Syn-Ake works topically with a gentler, partial relaxation that softens wrinkles without freezing facial expression.

Why People Talk About It

Dynamic wrinkle reduction (forehead, crow's feet)

Preliminary

Non-injectable alternative to Botox

Preliminary

MMP inhibition and collagen protection

Limited

Antioxidant activity

Limited

How It Works

When you frown or squint, nerves release acetylcholine to tell facial muscles to contract. Over time, these repeated contractions create wrinkles. Syn-Ake blocks the receptor on the muscle side — like putting a lock on the door so the contraction signal can't get through. The muscles partially relax, and the wrinkles they create soften and smooth out.

Common Questions

Safety Information

Important Safety Notes

Common Side Effects

Well-tolerated topically at standard cosmeceutical concentrationsNo significant adverse effects reported in clinical or in vitro safety testingCytotoxicity and genotoxicity testing confirmed safe dosage parameters

Cautions

• Not FDA-approved as a drug — marketed as a cosmeceutical ingredient
• Topical efficacy is limited by skin penetration — not as potent as injectable muscle relaxants
• Clinical studies often use multi-ingredient formulations, making it hard to isolate Syn-Ake's specific contribution
• Over-the-counter products vary widely in concentration and formulation quality

What We Don't Know

Long-term effects of chronic topical nmAChR antagonism on facial muscles are not studied. Whether meaningful receptor blockade occurs through intact skin at cosmeceutical concentrations is debated. Most clinical data comes from manufacturer-sponsored studies (DSM/Pentapharm). Independent clinical replication is limited.

Published Research

3 studies

The effect of a serum containing acetyl hexapeptide-8, dipeptide diaminobutyroyl benzylamide diacetate and gluconolactone on skin biomarkers, wrinkles and skin texture.

Clinical TrialPMID: 41668671

Anti-aging activity of Syn-Ake peptide by in silico approaches and in vitro tests.

PreclinicalPMID: 37349941

Viper Venom and Synthetic Peptides: Emerging Active Ingredients in Anti-Ageing Cosmeceuticals.

Review

Mechanism of Action

Syn-Ake (dipeptide diaminobutyroyl benzylamide diacetate) is a synthetic analog of Waglerin-1, a 22-amino acid peptide from Tropidolaemus wagleri venom. It acts as a reversible competitive antagonist at the epsilon (ε) subunit of the muscular nicotinic acetylcholine receptor (nmAChR), blocking acetylcholine binding and inhibiting muscle depolarization. At 0.5 mM, it reduces muscle contraction by 82% in isolated tissue preparations within 2 hours. This postsynaptic mechanism is complementary to presynaptic approaches like Argireline (SNARE complex inhibition) and SNAP-8. In silico studies demonstrate binding to MMP-13 (strongest), MMP-8, and MMP-1, suggesting additional anti-aging activity through matrix metalloproteinase inhibition that would protect collagen and elastin from enzymatic degradation. SIRT1 binding at -9.32 kcal/mol and dose-dependent DPPH radical scavenging indicate ancillary antioxidant and sirtuin-modulating properties. A 2026 clinical study of a serum containing Syn-Ake plus Argireline showed 35-69% static wrinkle improvement and 10-13% dynamic wrinkle improvement over 12 weeks.

Evidence Snapshot

Overall Confidence30%

Human Clinical Evidence

Limited. A controlled clinical study with 4% Syn-Ake over 28 days showed statistically significant wrinkle reduction (manufacturer data, DSM/Pentapharm). A 2026 clinical study (50 participants, 12 weeks) of a multi-peptide serum containing Syn-Ake and Argireline showed 35-69% static wrinkle improvement, 10-13% dynamic wrinkle improvement, and significant gains in smoothness, elasticity, and firmness (PMID: 41668671). However, multi-ingredient formulations make attribution to Syn-Ake specifically difficult.

Animal / Preclinical

Limited. Primarily in vitro: 82% muscle contraction reduction at 0.5 mM in isolated tissue preparations. Molecular docking and dynamics simulations confirmed stable binding to nmAChR, MMP-13, MMP-1, and SIRT1 (PMID: 37349941). Cytotoxicity and genotoxicity testing confirmed safety parameters.

Mechanistic Rationale

Moderate. The nmAChR antagonism mechanism is pharmacologically sound and well-characterized for Waglerin-1 venom peptides. The synthetic tripeptide's ability to replicate this activity topically through intact skin at cosmeceutical concentrations is the key question — in vitro receptor binding is demonstrated, but in vivo transdermal delivery efficiency is uncertain.

Forms & Administration

Syn-Ake is used topically in cosmeceutical formulations — serums, creams, and eye treatments. Standard concentrations are 1-4% in finished products. Often combined with Argireline (presynaptic) and/or Matrixyl (collagen stimulation) for multi-target anti-aging. Applied to clean skin, typically twice daily. No prescription required for cosmeceutical products.

Use Cases & Evidence Levels

Dynamic wrinkle reduction (forehead, crow's feet)

Preliminary30%

Non-injectable alternative to Botox

Preliminary30%

MMP inhibition and collagen protection

Limited15%

Antioxidant activity

Limited15%

Safety Profile

Safety Information

Common Side Effects

Cautions

• Not FDA-approved as a drug — marketed as a cosmeceutical ingredient
• Topical efficacy is limited by skin penetration — not as potent as injectable muscle relaxants
• Clinical studies often use multi-ingredient formulations, making it hard to isolate Syn-Ake's specific contribution
• Over-the-counter products vary widely in concentration and formulation quality

What We Don't Know

Published Research

3 studies

The effect of a serum containing acetyl hexapeptide-8, dipeptide diaminobutyroyl benzylamide diacetate and gluconolactone on skin biomarkers, wrinkles and skin texture.

Clinical TrialPMID: 41668671

Anti-aging activity of Syn-Ake peptide by in silico approaches and in vitro tests.

PreclinicalPMID: 37349941

Viper Venom and Synthetic Peptides: Emerging Active Ingredients in Anti-Ageing Cosmeceuticals.

Review

Related Peptides

Argireline

ModerateBeginner

A cosmetic peptide that reduces wrinkles by inhibiting neurotransmitter release at the neuromuscular junction, often called 'topical Botox.'

SNAP-8

EmergingBeginner

A cosmetic peptide that reduces the appearance of wrinkles by modulating neuromuscular junction signaling.

Matrixyl

ModerateBeginner

A collagen-stimulating cosmetic peptide that signals skin to produce more collagen and extracellular matrix proteins.

Palmitoyl Tripeptide-1

ModerateBeginner

A collagen-boosting cosmetic peptide that mimics the body's wound-healing signal to stimulate collagen and elastin production in the skin.

GHK-Cu

ModerateBeginner

A naturally occurring copper-binding peptide with extensive research on skin remodeling, wound healing, and anti-aging.

Rigin

PreliminaryBeginner

An immunomodulatory tetrapeptide derived from human IgG, used in cosmeceuticals as Palmitoyl Tetrapeptide-7 to suppress skin inflammation (IL-6) and support anti-aging skin repair.

Quick Facts

Class: Cosmeceutical Peptide
Evidence: Preliminary
Safety: Moderate Data
Updated: Apr 2026
Citations: 3PubMed

Also known as

Dipeptide Diaminobutyroyl Benzylamide DiacetateSynthetic Waglerin-1Snake Venom Peptide

Evidence Score

Overall Confidence30%

Clinical Trials

View Clinical Trials

Links to ClinicalTrials.gov for reference. Listing does not imply endorsement.